Apellis Pharmaceuticals (NASDAQ:APLS) received a strong-buy rating from Evercore ISI.

Evercore ISI raised Apellis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday…

Read More: https://www.marketbeat.com/instant-alerts/nasdaq-apls-upgrade-2024-11-02/